Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.

RATIONALE Little is known regarding the application of therapeutic drug monitoring for treatment of Mycobacterium avium complex (MAC) lung disease. OBJECTIVES To evaluate drug interactions of multidrug regimens and clinical usefulness of therapeutic drug monitoring in the management of MAC lung disease. METHODS A total of 130 patients with MAC lung disease and 60 patients with Mycobacterium abscessus complex lung disease were enrolled in this study. All of the MAC patients were treated with multidrug regimens that included clarithromycin (CLR), rifampin (RIF) or rifabutin (RFB), and ethambutol (EMB), and the plasma drug concentrations of CLR, RIF, and EMB were measured. MEASUREMENTS AND MAIN RESULTS Peak plasma CLR concentrations were lower in patients with MAC lung disease who received daily (median, 0.3 μg/ml) or intermittent (median, 0.2 μg/ml) therapy with CLR in conjunction with RIF in both groups, compared with those diagnosed with M. abscessus complex lung disease who received CLR without RIF (median, 3.8 μg/ml; P < 0.05). The proportion of patients with MAC lung disease who received daily therapy and whose plasma CLR levels were below the target range of 2 μg/ml was 97% (96 of 99), and this rate was 100% (21 of 21) among patients with MAC lung disease who received intermittent therapy. The peak plasma drug concentrations and the peak plasma drug concentration/minimal inhibitory concentration ratios of CLR, RIF, and EMB did not differ between patients with unfavorable treatment outcomes and those with favorable outcomes. CONCLUSIONS Low plasma CLR concentrations were common in patients treated for MAC lung disease. However, there was no association between low plasma CLR concentrations and treatment outcomes. Therefore, therapeutic drug monitoring may not be beneficial in managing the therapy of patients with MAC lung disease.

[1]  Young Kil Park,et al.  Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. , 2009, American journal of respiratory and critical care medicine.

[2]  K. Fukunaga,et al.  Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. , 2009, Chest.

[3]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[4]  C. Daley,et al.  Pulmonary non-tuberculous mycobacterial infections. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  C. Peloquin,et al.  Using therapeutic drug monitoring to dose the antimycobacterial drugs. , 1997, Clinics in chest medicine.

[6]  L. Young.  Mycobacterium avium complex infection. , 1988, The Journal of infectious diseases.

[7]  B. Strandvik,et al.  Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. , 1999, The European respiratory journal.

[8]  L. Heifets.  MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs , 1988, Antimicrobial Agents and Chemotherapy.

[9]  R. Wallace,,et al.  Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. , 1995, The Journal of infectious diseases.

[10]  Y. Obase,et al.  Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[11]  M. Boeree,et al.  Therapeutic drug monitoring in the treatment of tuberculosis patients. , 2012, Pulmonary pharmacology & therapeutics.

[12]  Young Kil Park,et al.  Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.

[13]  S. Holland,et al.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. , 2012, American journal of respiratory and critical care medicine.

[14]  U. Pennsylvania,et al.  Clinical and Laboratory Standards Institute , 2019, Springer Reference Medizin.

[15]  S. Garay,et al.  Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. , 2006, American journal of respiratory and critical care medicine.

[16]  W. Yew.  Therapeutic drug monitoring in antituberculosis chemotherapy. , 1998, Therapeutic drug monitoring.

[17]  Mary Ann Blosky,et al.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. , 2010, American journal of respiratory and critical care medicine.

[18]  S. Field,et al.  Mycobacterium avium complex pulmonary disease in patients without HIV infection. , 2004, Chest.

[19]  R. Wallace,,et al.  Drug intolerance to high-dose clarithromycin among elderly patients. , 1993, Diagnostic microbiology and infectious disease.

[20]  E. Y. Kim,et al.  Treatment Outcome of Combination Therapy Including Clarithromycin for Mycobacterium avium Complex Pulmonary Disease , 2011, The Korean journal of internal medicine.

[21]  R. Wallace,,et al.  Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Mikio Oka,et al.  A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. , 2007, Respiratory medicine.

[23]  J. Grosset,et al.  Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial Infections , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[24]  Yoshihiro Kobashi,et al.  The Microbiological and Clinical Effects of Combined Therapy according to Guidelines on the Treatment of Pulmonary Mycobacterium avium Complex Disease in Japan – Including a Follow-Up Study , 2006, Respiration.

[25]  M. Kimerling,et al.  Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. , 1998, Chest.

[26]  C. Peloquin.  Mycobacterium avium Complex Infection , 1997, Clinical pharmacokinetics.

[27]  F. Fountain,et al.  Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. , 2001, Chest.

[28]  A. Ishizaka,et al.  Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. , 2009, Pulmonary pharmacology & therapeutics.

[29]  J. Zuckerman,et al.  Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). , 2011, The Medical clinics of North America.

[30]  C. Daley,et al.  The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.

[31]  Y. Obase,et al.  Clinical usefulness of combination chemotherapy for pulmonary Mycobacterium avium complex disease. , 2010, The Journal of infection.

[32]  C. Peloquin.  Therapeutic Drug Monitoring in the Treatment of Tuberculosis , 2012, Drugs.

[33]  E. Houpt,et al.  Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA , 2010, Emerging infectious diseases.

[34]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .